title: Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.
abstract: Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.
authors.affiliation: Department of Dermatology, Allergology and Venerology, University Hospital Schleswig-Holstein, Kiel, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hotze
authors.forename: H
authors.initials: H
authors.lastname: Baurecht
authors.forename: E
authors.initials: E
authors.lastname: Rodríguez
authors.forename: N
authors.initials: N
authors.lastname: Chapman-Rothe
authors.forename: M
authors.initials: M
authors.lastname: Ollert
authors.forename: R
authors.initials: R
authors.lastname: Fölster-Holst
authors.forename: J
authors.initials: J
authors.lastname: Adamski
authors.forename: T
authors.initials: T
authors.lastname: Illig
authors.forename: J
authors.initials: J
authors.lastname: Ring
authors.forename: S
authors.initials: S
authors.lastname: Weidinger
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D000091344:Filaggrin Proteins; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics*; D000069444:Omalizumab; D010713:Phosphatidylcholines / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D010713:Phosphatidylcholines; D000069444:Omalizumab
keywords: anti-IgE; atopic dermatitis; filaggrin; metabolomics; omalizumab